Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab
The agreement grants Knight Therapeutics rights to market the medicine for mycosis fungoides and Sézary syndrome subtypes.
Therapy Area
Daiichi Sankyo, MSD withdraw cancer drug application
Innovent expands Phase III MarsLight-11 trial to non-squamous NSCLC
Orum to begin Phase I trial of ORM-1153 after FDA clearance
Johnson & Johnson’s multiple myeloma treatment secures EC approval
First patient dosed with DISP-10 in Dispatch Bio’s cancer trial
FDA issues complete response letter to Replimune’s RP1 for melanoma
BioNTech and DualityBio report positive data for trastuzumab pamirtecan
